MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
Aeris Therapeutics, Woburn, Mass.
Aeris is developing an adhesive foam for lung-volume reduction treatments.
David Dove, President & CEO
Edward Ingenito, CSO & Medical Director
The AeriSeal System for Lung Volume Reduction was developed to provide the clinical benefits of lung volume reduction surgery without the associated morbidity and mortality.
LVRS entails the surgical resection of the most diseased lung tissue to improve function in the remaining healthier lung regions. LVRS has demonstrated therapeutic effectiveness but is a highly invasive procedure with significant associated morbidity and mortality, resulting in limited adoption.
AeriSeal is delivered using a bronchoscope to direct treatment to the most diseased areas of the patient’s lungs which have been identified by chest CT imaging. AeriSeal adhesive foam flows into the target area as a liquid where it polymerizes and adheres to the adjacent tissue. As the air contained within the foam diffuses out, the treated areas collapse, resulting in site-specific volume loss.
The interim study results indicate that AeriSeal therapy results in therapeutic lung volume reduction without the morbidity and mortality associated with LVRS.